EP3010590B1 - Dandruff (and scalp) treatment - Google Patents

Dandruff (and scalp) treatment Download PDF

Info

Publication number
EP3010590B1
EP3010590B1 EP14738904.3A EP14738904A EP3010590B1 EP 3010590 B1 EP3010590 B1 EP 3010590B1 EP 14738904 A EP14738904 A EP 14738904A EP 3010590 B1 EP3010590 B1 EP 3010590B1
Authority
EP
European Patent Office
Prior art keywords
plasma
scalp
treatment
dandruff
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP14738904.3A
Other languages
German (de)
French (fr)
Other versions
EP3010590A1 (en
Inventor
Frédéric Woodland
Fabrice OSOLIN
Jean-Yves Legendre
Gabin Vic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LOreal SA filed Critical LOreal SA
Publication of EP3010590A1 publication Critical patent/EP3010590A1/en
Application granted granted Critical
Publication of EP3010590B1 publication Critical patent/EP3010590B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/44Applying ionised fluids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00Preparations for care of the hair
    • A61Q5/006Antidandruff preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/83Electrophoresis; Electrodes; Electrolytic phenomena

Definitions

  • the present invention is directed towards proposing a novel treatment for the prevention and/or treatment of disorders, in particular aesthetic disorders, of the scalp.
  • the invention relates to dandruff disorders of the scalp.
  • the scalp is an epidermis that undergoes continual renewal, like the rest of the skin tissue, and that is rich in sebaceous glands.
  • the scalp undergoes renewal by removing the surface cells of the skin, without this renewal being felt or seen.
  • excessive renewal of the cells of the stratum corneum of the scalp may lead to the formation of large, thick patches of cells that are visible to the naked eye, known as "dandruff".
  • the Malassezia sp. genus consists of lipophilic yeasts normally present on the skin of human beings and of certain warm-blooded animals. Their distribution depends on age, on sebaceous gland activity, and on certain pathological conditions.
  • genus represents approximately 45% of the normal commensal flora at the surface of the scalp in dandruff-free individuals, but can represent 75% of the flora in the case of dandruff, and up to 85% in the case of associated seborrhoeic dermatitis.
  • the other microorganisms generally present at the surface of the scalp are micrococci and Propionobacterium.
  • Dandruff conditions generally respond to various local or systemic antifungal treatments.
  • various preparations combining antifungals and anti-seborrhoeic agents have been proposed in order to treat severe dandruff conditions.
  • Antifungal-based treatments demonstrate a certain efficacy on dandruff conditions.
  • WO 2012/103877 describes a process for treating the hair using a dielectric plasma.
  • WO 2004/105810 relates to a process for treating biological materials with an atmospheric plasma.
  • KR2006025825 describes an apparatus for dyeing the hair using an atmospheric cold plasma.
  • DE10238931 describes an apparatus for preparing a nail to receive a varnish.
  • CN101259036 describes a plasma generator in the form of a pencil, for treating the skin and removing blackheads.
  • DE102009060627 discloses an electrode arrangement for the dielectric barrier plasma treatment of a skin surface.
  • WO 2011/058301 describes a treatment apparatus used in cosmetics and in the dental field, using a cold plasma.
  • KR20090400156 discloses an anti-wrinkle plasma treatment apparatus.
  • WO 2011/144344 A2 discloses a device for at least partially sterilising a contaminated surface, using a cold plasma; various electrode arrangements for producing the plasma are described and a large number of applications are mentioned, for instance deodorising.
  • WO00/15168 teaches a topical antifungal composition for treating hair, skin and scalp for preventing dandruff.
  • the present invention meets this objective by virtue of a device according to claim 1.
  • the present specification also discloses the cosmetic use of a cold atmospheric plasma for preventing and/or treating aesthetic disorders of the healthy scalp, and in particular dandruff conditions of the healthy scalp.
  • the invention offers a solution which is effective right from the beginning of the treatment, and which is relatively long-lasting, rapid and easy to carry out.
  • Another advantage of the invention lies in the possibility of not calling upon any biocidal compound to be applied in the form of a lotion or shampoo for example.
  • the term "preventing" means reducing the risk of manifestation of the phenomenon under consideration.
  • the present description also discloses a cosmetic process for treating and/or preventing aesthetic disorders of the healthy scalp in an individual, comprising the exposure of the scalp to a cold atmospheric plasma.
  • the disclosed process is in particular advantageously carried out in individuals exhibiting a dandruff condition of the scalp.
  • a subject of the invention is also a device for use in treating the scalp, comprising:
  • a plasma is an ionised gas which can also generate reactive species, produced by the discharge resulting in the plasma.
  • a cold atmospheric plasma is a plasma which does not cause any excessive heating of the substrate exposed to the plasma.
  • DBD Dielectric Barrier Discharge
  • plasma-torch In indirect plasmas, the plasma is generated between two electrodes and is then directed towards the substrate using a gas stream.
  • plasma-torch One of the main technologies is known as "plasma-torch”.
  • Hybrid plasmas known as corona plasmas, ally the mode of production of a direct plasma and the properties of indirect plasmas.
  • the scalp acts as the counter electrode and the area located under the electrode is treated.
  • the invention is not limited in terms of gas.
  • the preferential gas is air.
  • direct plasmas and even more preferentially those of DBD type, are preferred in the invention.
  • the process according to the invention comprises exposing the scalp to a cold atmospheric plasma.
  • the treatment area preferentially extends to the whole of the scalp.
  • the treatment time is adjusted according to the desired result.
  • the area of inhibition may be extended, thereby making it possible to treat a larger surface area than the surface area of the electrode or of the plasma source.
  • the treatment time is preferentially between 1" and 10', and more preferentially between 1" and 5'. This treatment time is entirely compatible with cosmetic use of a plasma generator for the treatment of dandruff conditions.
  • the plasma can be produced while maintaining the electrode or the source of plasma production at a controlled distance while it is moved at the surface of the scalp.
  • This movement can be carried out manually or in an automated manner.
  • the latter can be assisted, where appropriate, by a guidance structure placed around the person's head.
  • the hair may be locally parted so as to facilitate access to the scalp, by means of a comb, for example.
  • the plasma production may be automatically interrupted over time, the generator stopping, for example, after a predefined operating period or when it is detected that the whole scalp has been treated.
  • the treatment may be repeated periodically, at intervals of 2 days to 1 month, for example.
  • the treatment process comprises a topical application of a cosmetic composition
  • the penetration of the active agent(s) for treating the scalp may be facilitated, in particular owing to the fact that the plasma may decrease the lipid barrier function.
  • the surface of the scalp may also be rendered more hydrophilic.
  • the composition applied may in particular comprise one or more antidandruff active agents.
  • antidandruff active agent is intended to mean a compound capable of preventing the appearance of dandruff, reducing the number of dandruff flakes and/or making said dandruff disappear entirely.
  • An antidandruff active agent that is suitable for use in the invention may be chosen in particular from:
  • the plasma is generated by means of any suitable device which makes it possible to expose the scalp to a cold atmospheric plasma.
  • the emission of plasma is preferably carried out from a generator comprising a handpiece or in the form of a handpiece, the ergonomics of which are compatible with the application on the scalp.
  • An example of a device that can be used is described later, with reference to Figure 2 .
  • the device is arranged so as to provide uniform exposure of the scalp, by controlling the strength of the plasma produced.
  • the device may be arranged so as to maintain a predefined distance between the electrode or source of production of the plasma and the scalp, for example by virtue of a guide which bears against the scalp when the electrode or the source is moved relative to the scalp.
  • This guide may have a curved surface which approximately moulds the curvature of the scalp.
  • the device may be arranged so as to locally part the hair in order to clear the scalp and facilitate the action of the plasma, and may comprise one or more comb teeth for this purpose.
  • the position of the device relative to the scalp when said device is moved may be detected, for example by means of accelerometers and/or of a camera, and the plasma production may be automatically controlled according to the position of the device so as to ensure the most complete and uniform precise treatment; for example, if it is detected that the device is again passing over a site on the scalp that has already been treated, the plasma production may be momentarily interrupted or reduced.
  • the device may be arranged so as to detect, for example by means of a camera, a movement of the device which is too fast to allow sufficient treatment, and to make the user aware of this.
  • the device may be mains-operated, rechargeable battery-operated and/or battery-operated.
  • the device may comprise a member for massaging the scalp, the action of which may or may not be concomitant with the plasma treatment.
  • a growth medium (agar) was inoculated with a Malassezia culture.
  • the agar was then subjected to a plasma treatment of DBD type for a period ranging from 10" to 10'.
  • the inoculated dishes (3 per series of tests) were divided into quadrants and exposed to the plasma gas respectively for 10 s, 30 s and 60 s on three respective quadrants for the first series of tests, and 1 min, 5 min and 10 min for the second series of tests.
  • the dishes were then incubated at 30-33°C for between 4 and 5 days.
  • the antifungal effect of the plasma gas was evaluated by measuring the surface area of inhibition of the Malassezia strain exposed, by means of the Cell F image analysis software (Olympus).
  • the surface area treated corresponds to the surface area of the electrode, i.e. approximately 1 cm 2 .
  • the exposure to the plasma had an antifungal effect on the two strains tested ( Malessezia globosa and Malassezia restrict ) .
  • the effect appears from as early as 10" of treatment and the surface area of inhibition around the area exposed increases as a function of exposure time, until it covers several cm 2 .
  • Malassezia restricta strain is more sensitive than Malassezia globosa.
  • Figure 2 shows an example of a device 10 for treating the scalp according to the invention.
  • This device comprises a handpiece 11 to be moved on the scalp.
  • the plasma generator is, for example, of DBD type, and in this case, the handpiece 11 may comprise an electrode 12 covered with a dielectric material.
  • the electrode 12 is supplied with high-voltage pulses, in a manner known per se.
  • the scalp serves as a counter electrode, and receives a harmless electric current.
  • the device 10 comprises a guide 15 for maintaining the electrode 12 at a predefined distance from the scalp C.
  • This guide 15 is also arranged so as to part the hair H upstream of the electrode 12, considering the direction of movement of the handpiece 11 relative to the scalp.
  • This guide 15 may be in the form of a comb tooth with a rounded end piece, as illustrated.
  • the treatment may also be carried out differently, for example by being combined with the topical application of a cosmetic composition, in particular comprising an antidandruff active agent, or with the taking of a food supplement, before, during or after the plasma treatment.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Birds (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)
  • Electrotherapy Devices (AREA)

Description

  • The present invention is directed towards proposing a novel treatment for the prevention and/or treatment of disorders, in particular aesthetic disorders, of the scalp. In particular, the invention relates to dandruff disorders of the scalp.
  • The scalp is an epidermis that undergoes continual renewal, like the rest of the skin tissue, and that is rich in sebaceous glands.
  • Normally, the scalp undergoes renewal by removing the surface cells of the skin, without this renewal being felt or seen. However, excessive renewal of the cells of the stratum corneum of the scalp, for various reasons, may lead to the formation of large, thick patches of cells that are visible to the naked eye, known as "dandruff".
  • By way of example of factors which promote the appearance of dandruff, mention may be made of stress, the winter period, a lack of moisturisation or the colonisation of the skin or hair follicles by the yeast Malassezia sp. The Malassezia sp. genus consists of lipophilic yeasts normally present on the skin of human beings and of certain warm-blooded animals. Their distribution depends on age, on sebaceous gland activity, and on certain pathological conditions. The Malassezia sp. genus represents approximately 45% of the normal commensal flora at the surface of the scalp in dandruff-free individuals, but can represent 75% of the flora in the case of dandruff, and up to 85% in the case of associated seborrhoeic dermatitis. The other microorganisms generally present at the surface of the scalp are micrococci and Propionobacterium.
  • Dandruff conditions generally respond to various local or systemic antifungal treatments. Thus, various preparations combining antifungals and anti-seborrhoeic agents have been proposed in order to treat severe dandruff conditions. Antifungal-based treatments demonstrate a certain efficacy on dandruff conditions.
  • The use of a chemical antifungal integrated into a shampoo that will inhibit yeasts of Malassezia type at the surface of the scalp is relatively effective, but after use of the antidandruff shampoo is stopped, the dandruff reappears quite rapidly.
  • Moreover, numerous patent application publications relate to the use of plasmas in the medical field and the cosmetics field.
  • International application WO 2012/104332 discloses a deodorant treatment process by combining a cosmetic composition and a plasma.
  • WO 2012/103877 describes a process for treating the hair using a dielectric plasma.
  • WO 2004/105810 relates to a process for treating biological materials with an atmospheric plasma.
  • KR2006025825 describes an apparatus for dyeing the hair using an atmospheric cold plasma.
  • DE10238931 describes an apparatus for preparing a nail to receive a varnish.
  • CN101259036 describes a plasma generator in the form of a pencil, for treating the skin and removing blackheads.
  • DE102009060627 discloses an electrode arrangement for the dielectric barrier plasma treatment of a skin surface.
  • WO 2011/058301 describes a treatment apparatus used in cosmetics and in the dental field, using a cold plasma.
  • KR20090400156 discloses an anti-wrinkle plasma treatment apparatus.
  • WO 2011/144344 A2 discloses a device for at least partially sterilising a contaminated surface, using a cold plasma; various electrode arrangements for producing the plasma are described and a large number of applications are mentioned, for instance deodorising.
  • WO00/15168 teaches a topical antifungal composition for treating hair, skin and scalp for preventing dandruff.
  • There remains a need for novel solutions capable of exerting a beneficial action on scalp conditions, in particular of eliminating or reducing the appearance of dandruff.
  • The present invention meets this objective by virtue of a device according to claim 1.
  • The present specification also discloses the cosmetic use of a cold atmospheric plasma for preventing and/or treating aesthetic disorders of the healthy scalp, and in particular dandruff conditions of the healthy scalp.
  • The invention offers a solution which is effective right from the beginning of the treatment, and which is relatively long-lasting, rapid and easy to carry out.
  • Another advantage of the invention lies in the possibility of not calling upon any biocidal compound to be applied in the form of a lotion or shampoo for example.
  • For the purposes of the present invention, the term "preventing" means reducing the risk of manifestation of the phenomenon under consideration.
  • The present description also discloses a cosmetic process for treating and/or preventing aesthetic disorders of the healthy scalp in an individual, comprising the exposure of the scalp to a cold atmospheric plasma.
  • The disclosed process is in particular advantageously carried out in individuals exhibiting a dandruff condition of the scalp.
  • According to another of its aspects, a subject of the invention is also a device for use in treating the scalp, comprising:
    • a member for producing cold atmospheric plasma, which makes it possible to expose the scalp to the plasma,
    • a guide configured so as to bear against the scalp and to allow said member to move relative to the scalp at a predefined distance therefrom, in particular of between 0.5 and 15 mm, preferentially between 2 and 6 mm.
    Plasma
  • A plasma is an ionised gas which can also generate reactive species, produced by the discharge resulting in the plasma. A cold atmospheric plasma is a plasma which does not cause any excessive heating of the substrate exposed to the plasma.
  • Three families of cold atmospheric plasmas are available, namely direct, indirect and hybrid plasmas.
  • In direct plasmas, it is the substrate which acts as the counter electrode required for producing the plasma; the plasma is therefore generated between the electrode and the substrate. One of the main direct plasma technologies is the plasma known as DBD (Dielectric Barrier Discharge).
  • In indirect plasmas, the plasma is generated between two electrodes and is then directed towards the substrate using a gas stream. One of the main technologies is known as "plasma-torch".
  • Hybrid plasmas, known as corona plasmas, ally the mode of production of a direct plasma and the properties of indirect plasmas.
  • In the context of a direct or hybrid plasma, the scalp acts as the counter electrode and the area located under the electrode is treated.
  • Cold atmospheric plasmas make it possible to use various gases (air, helium, oxygen, etc). The invention is not limited in terms of gas. In direct plasma, the preferential gas is air.
  • In the context of the use of plasma alone, direct plasmas, and even more preferentially those of DBD type, are preferred in the invention.
  • Treatment process
  • The process according to the invention comprises exposing the scalp to a cold atmospheric plasma.
  • The treatment area preferentially extends to the whole of the scalp.
  • It may then be necessary, in order to carry out the treatment, to move, relative to the scalp, a member which provides local production of the plasma.
  • The treatment time is adjusted according to the desired result.
  • Depending on the exposure time, the area of inhibition may be extended, thereby making it possible to treat a larger surface area than the surface area of the electrode or of the plasma source.
  • The treatment time is preferentially between 1" and 10', and more preferentially between 1" and 5'. This treatment time is entirely compatible with cosmetic use of a plasma generator for the treatment of dandruff conditions.
  • A 10" exposure already makes it possible to obtain an entirely satisfactory inhibition of Malassezia yeasts.
  • The plasma can be produced while maintaining the electrode or the source of plasma production at a controlled distance while it is moved at the surface of the scalp.
  • This movement can be carried out manually or in an automated manner. In the case of manual movement, the latter can be assisted, where appropriate, by a guidance structure placed around the person's head.
  • During the movement, the hair may be locally parted so as to facilitate access to the scalp, by means of a comb, for example.
  • The plasma production may be automatically interrupted over time, the generator stopping, for example, after a predefined operating period or when it is detected that the whole scalp has been treated.
  • The treatment may be repeated periodically, at intervals of 2 days to 1 month, for example.
  • When the treatment process comprises a topical application of a cosmetic composition, before, during or after exposure to the plasma, the penetration of the active agent(s) for treating the scalp may be facilitated, in particular owing to the fact that the plasma may decrease the lipid barrier function. The surface of the scalp may also be rendered more hydrophilic. The composition applied may in particular comprise one or more antidandruff active agents.
  • Active agents Antidandruff active agents
  • The term "antidandruff active agent" is intended to mean a compound capable of preventing the appearance of dandruff, reducing the number of dandruff flakes and/or making said dandruff disappear entirely.
  • An antidandruff active agent that is suitable for use in the invention may be chosen in particular from:
    • 1-hydroxy-2-pyridone derivatives, such as 1-hydroxy-4-methyl-2-pyridone, 1-hydroxy-6-methylpyridone, 1-hydroxy-4,6-dimethyl-2-pyridone, 1-hydroxy-4-methyl-6-(2,4,4-trimethylpentyl)-2-pyridone, 1-hydroxy-4-methyl-6-cyclohexyl-2-pyridone, 1-hydroxy-4-methyl-6-(methylcyclohexyl)2-pyridone, 1-hydroxy-4-methyl-6-(2-bicyclo[2,2,1]heptyl)-2-pyridone, 1-hydroxy-4-methyl-6(4-methylphenyl)-2-pyridone, 1-hydroxy-4-methyl-6[1-[4-nitrophenoxy]butyl]-2-pyridone, 1-hydroxy-4-methyl-6-(4-cyanophenoxymethyl-2-pyridone), 1-hydroxy-4-methyl-6-(phenylsulfonylmethyl)-2-pyridone, 1-hydroxy-4-methyl-6-(4-bromobenzyl)-2-pyridone and salts thereof; by way of preferred 1-hydroxy-2-pyridone derivative, mention may be made of the product sold by the company Hoechst under the name octopyrox (1-hydroxy-4-methyl-6-(2,4,4-trimethylpenthyl)-2-pyridone, monoethanolamine salt;
    • pyridinethione salts, in particular the calcium, magnesium, barium, strontium, zinc, cadmium, tin and zirconium salts. The zinc salt of pyridinethione is particularly preferred. The zinc salt of pyridinethione is sold in particular under the name zinc omadine by the company Olin;
    • trihalocarbamides of formula:
      Figure imgb0001
      in which Z represents a halogen atom such as chlorine or a C1-C4 trihaloalkyl group such as CF3;
    • triclosan, represented by the formula:
      Figure imgb0002
    • azole compounds such as climbazole, ketoconazole, clotrimazole, econazole, isoconazole and miconazole;
    • antifungal polymers such as amphotericin B or nystatin;
    • selenium sulfides, in particular those of formula SxSe8-x, x ranging from 1 to 7;
    • sulfur in its various forms, cadmium sulfide, allantoin, coal or wood tars and derivatives thereof, in particular cade oil, salicylic acid, undecylenic acid, fumaric acid, and allylamines such as terbinafine;
    • ellagic acid;
    • selenium disulfide.
    Treatment device
  • The plasma is generated by means of any suitable device which makes it possible to expose the scalp to a cold atmospheric plasma.
  • The emission of plasma is preferably carried out from a generator comprising a handpiece or in the form of a handpiece, the ergonomics of which are compatible with the application on the scalp. A Kinpen source sold by the company Neoplas tools GmbH, or a source in pen format as described in application CN101259036 , or else a source in the form of a comb adapted for exposure of the scalp to the plasma, is for example used. An example of a device that can be used is described later, with reference to Figure 2.
  • Preferably, the device is arranged so as to provide uniform exposure of the scalp, by controlling the strength of the plasma produced.
  • The device may be arranged so as to maintain a predefined distance between the electrode or source of production of the plasma and the scalp, for example by virtue of a guide which bears against the scalp when the electrode or the source is moved relative to the scalp. This guide may have a curved surface which approximately moulds the curvature of the scalp.
  • The device may be arranged so as to locally part the hair in order to clear the scalp and facilitate the action of the plasma, and may comprise one or more comb teeth for this purpose.
  • The position of the device relative to the scalp when said device is moved may be detected, for example by means of accelerometers and/or of a camera, and the plasma production may be automatically controlled according to the position of the device so as to ensure the most complete and uniform precise treatment; for example, if it is detected that the device is again passing over a site on the scalp that has already been treated, the plasma production may be momentarily interrupted or reduced.
  • The device may be arranged so as to detect, for example by means of a camera, a movement of the device which is too fast to allow sufficient treatment, and to make the user aware of this.
  • The device may be mains-operated, rechargeable battery-operated and/or battery-operated.
  • The device may comprise a member for massaging the scalp, the action of which may or may not be concomitant with the plasma treatment.
  • Tests
  • In vitro tests were carried out which demonstrate that a plasma treatment makes it possible to inhibit the growth of Malassezia yeasts from a relatively short exposure time onwards.
  • A growth medium (agar) was inoculated with a Malassezia culture.
  • The agar was then subjected to a plasma treatment of DBD type for a period ranging from 10" to 10'.
  • The inoculated dishes (3 per series of tests) were divided into quadrants and exposed to the plasma gas respectively for 10 s, 30 s and 60 s on three respective quadrants for the first series of tests, and 1 min, 5 min and 10 min for the second series of tests. The dishes were then incubated at 30-33°C for between 4 and 5 days.
  • At the end of the incubation period, all of the agar dishes were photographed.
  • The antifungal effect of the plasma gas was evaluated by measuring the surface area of inhibition of the Malassezia strain exposed, by means of the Cell F image analysis software (Olympus).
  • The surface area treated corresponds to the surface area of the electrode, i.e. approximately 1 cm2.
  • Results
  • Under the conditions of the test, the exposure to the plasma had an antifungal effect on the two strains tested (Malessezia globosa and Malassezia restrict). The effect appears from as early as 10" of treatment and the surface area of inhibition around the area exposed increases as a function of exposure time, until it covers several cm2.
  • Malassezia restricta
  • Malassezia restricta (inhibition surface area in cm2)
    Treatment time Test 1 Test 2 Test 3 Mean
    10 s = 0.17 min 0.612 0.879 1.366 0.952
    30 s = 0.50 min 1.752 1.624 2.183 1.853
    1 min 2.456 2.87 4.058 3.128
    Mean of the two series for 1 minute: 2.564
    1 min 2.03 1.770 2.193 2.000
  • Malassezia globosa
  • Time (min) Malassezia globosa (inhibition surface area in cm2)
    Treatment time Test 1 Test 2 Test 3 Mean
    10 s = 0.17 min 0.162 0.37 0.318 0.283
    30 s = 0.5 min 0.769 0.633 0.588 0.663
    60 s = 1 min 0.959 0.774 0.872 0.868
    Mean of the two series for 1 minute: 0.817
    1 min 0.699 0.836 0.763 0.766
    5 min 2.121 1.657 1.889 1.889
    10 min 2.423 2.765 2.566 2.585
  • Under the conditions of the tests, the Malassezia restricta strain is more sensitive than Malassezia globosa.
  • The results are reported in the appended Figure 1.
  • Figure 2 shows an example of a device 10 for treating the scalp according to the invention.
  • This device comprises a handpiece 11 to be moved on the scalp.
  • The plasma generator is, for example, of DBD type, and in this case, the handpiece 11 may comprise an electrode 12 covered with a dielectric material.
  • The electrode 12 is supplied with high-voltage pulses, in a manner known per se.
  • The scalp serves as a counter electrode, and receives a harmless electric current.
  • The device 10 comprises a guide 15 for maintaining the electrode 12 at a predefined distance from the scalp C. This guide 15 is also arranged so as to part the hair H upstream of the electrode 12, considering the direction of movement of the handpiece 11 relative to the scalp. This guide 15 may be in the form of a comb tooth with a rounded end piece, as illustrated.
  • The invention is not limited to the examples that have just been described.
  • In particular, the treatment may also be carried out differently, for example by being combined with the topical application of a cosmetic composition, in particular comprising an antidandruff active agent, or with the taking of a food supplement, before, during or after the plasma treatment.

Claims (5)

  1. Device (10) for use in preventing and/or treating a dandruff condition of the scalp, comprising:
    - a member (12) for producing a cold atmospheric plasma, which makes it possible to expose the scalp to the plasma,
    - a guide (15) configured so as to bear against the scalp (C) and to allow said member to move relative to the scalp at a predefined distance therefrom, the distance being between 2 and 6 mm.
  2. Device for use
    according to Claim 1, the member for producing plasma belonging to a generator of direct type, preferably DBD type.
  3. Device for use according to Claim 1, the plasma being of hybrid type.
  4. Device for use according to Claim 1, the plasma being of indirect type.
  5. Device for use
    according to any one of the preceding claims, the gas used for the plasma production being air.
EP14738904.3A 2013-06-21 2014-06-20 Dandruff (and scalp) treatment Active EP3010590B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1355948A FR3007273B1 (en) 2013-06-21 2013-06-21 COSMETIC USE OF COLD PLASMA
PCT/IB2014/062487 WO2014203218A1 (en) 2013-06-21 2014-06-20 Cosmetic use of a cold plasma

Publications (2)

Publication Number Publication Date
EP3010590A1 EP3010590A1 (en) 2016-04-27
EP3010590B1 true EP3010590B1 (en) 2018-02-07

Family

ID=49003912

Family Applications (1)

Application Number Title Priority Date Filing Date
EP14738904.3A Active EP3010590B1 (en) 2013-06-21 2014-06-20 Dandruff (and scalp) treatment

Country Status (8)

Country Link
US (1) US20160136062A1 (en)
EP (1) EP3010590B1 (en)
JP (1) JP2016523859A (en)
KR (1) KR20160024928A (en)
CN (1) CN105339048A (en)
ES (1) ES2666903T3 (en)
FR (1) FR3007273B1 (en)
WO (1) WO2014203218A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018011371A (en) 2016-03-22 2019-02-13 Koninklijke Philips Nv A cold plasma device for treating skin.
CN106310524B (en) * 2016-08-29 2018-12-18 荣烜曼 A kind of handheld plasma cosmetic apparatus
KR102384849B1 (en) * 2017-05-08 2022-04-11 로레알 Cold-atmospheric plasma treatment with chemical or organic compounds to alter keratogenic matrix microbial flora
US11517639B2 (en) 2018-07-31 2022-12-06 L'oreal Generating cold plasma away from skin, and associated systems and methods
FR3090324B1 (en) * 2018-12-21 2021-12-10 Oreal Process for treating human keratin materials

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015168A1 (en) * 1998-09-10 2000-03-23 Danclar Wayne G Topical anti-fungal treatment for dandruff
ATE406867T1 (en) * 2001-07-18 2008-09-15 Unilever Nv COMPOSITIONS FOR THE TREATMENT OF HAIR AND/OR SCALP
DE10238931C1 (en) 2002-08-24 2003-07-31 Fh Hildesheim Holzminden Goe Finger or toe nail pre-treatment method for facilitating application of nail lacquer using gas discharge
DE10324926B3 (en) * 2003-06-03 2005-02-03 Fachhochschule Hildesheim/Holzminden/Göttingen Apparatus for treating a biological cell containing living cells with a plasma generated by a gas discharge
KR100595808B1 (en) 2004-09-17 2006-07-05 주식회사 다원시스 Hair dyeing apparatus using atmospheric pressure plasma
CA2651200C (en) * 2005-03-07 2015-11-03 Old Dominion University Plasma generator
EP2104450A1 (en) * 2007-01-17 2009-09-30 Lerner Medical Devices, Inc. Light source and fiber optic brush for light delivery
CN101259036A (en) 2007-03-06 2008-09-10 徐小羚 Minisize plasma pen for removing speckle of skin
KR20090040156A (en) 2007-10-19 2009-04-23 삼성전자주식회사 Skin wrinkle treating apparatus and method
RU2011142810A (en) * 2009-03-27 2013-05-10 Геркулес Инкорпорейтед AMINED POLYMERS AND THEIR APPLICATION IN WATER-BASED COMPOSITIONS
GB0919891D0 (en) 2009-11-13 2009-12-30 Linde Aktiengesellshcaft Apparatus for providing a modified gaseous species
DE102009060627B4 (en) * 2009-12-24 2014-06-05 Cinogy Gmbh Electrode arrangement for a dielectrically impeded plasma treatment
WO2011144344A2 (en) * 2010-05-19 2011-11-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Appliance for at least partially sterilizing a contaminated surface
DE102011003533A1 (en) 2011-02-02 2012-08-02 Beiersdorf Ag Deodorant skin film
DE102011010273A1 (en) 2011-02-02 2012-08-02 Cinogy Gmbh Method for treating human or animal hair and apparatus for carrying out the method
US20140207053A1 (en) * 2011-05-05 2014-07-24 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Device and method for the plasma treatment of surfaces and use of a device
WO2013040486A1 (en) * 2011-09-15 2013-03-21 Cold Plasma Medical Technologies, Inc. Cold plasma treatment devices and associated methods
JP2013077474A (en) * 2011-09-30 2013-04-25 Panasonic Corp Atmospheric pressure plasma generator

Also Published As

Publication number Publication date
EP3010590A1 (en) 2016-04-27
FR3007273A1 (en) 2014-12-26
US20160136062A1 (en) 2016-05-19
FR3007273B1 (en) 2015-07-31
CN105339048A (en) 2016-02-17
ES2666903T3 (en) 2018-05-08
WO2014203218A1 (en) 2014-12-24
JP2016523859A (en) 2016-08-12
KR20160024928A (en) 2016-03-07

Similar Documents

Publication Publication Date Title
EP3010590B1 (en) Dandruff (and scalp) treatment
JP6446065B2 (en) Niacinamide for inducing the formation of antimicrobial peptides
ATE533795T1 (en) NEUTRALIZED CATIONIC POLYMER, COMPOSITION WITH SAID POLYMER AND COSMETIC TREATMENT METHOD
JPH11502504A (en) Formulations and methods for reducing skin irritation
MX2013004214A (en) Use of monoamine oxidase inhibitors to improve epithelial biology.
KR20140053996A (en) Use of sphinganine to improve the visual appearance of skin and hair
US7326420B2 (en) Benzoyl peroxide compositions having increased potency
KR20170022787A (en) Oxidizing Agent For Hair Perm Formation Comprising Hydrogen Water And Method Of Hair Perm Formation Using The Same
WO2019121968A1 (en) Cosmetic treatment process using cold plasma and device for carrying out the process
MX2023006726A (en) Compositions comprising antimicrobials and (bio)-alkanediols for skin protection.
JP2012024048A (en) Deodorizer comprising unsaturated aldehyde blended with enzyme, and method of deodorization
RU2006123436A (en) APPLICATION OF PPAR RECEPTOR ACTIVATORS IN COSMETICS AND DERMATOLOGY
RU2477155C2 (en) Method of treating androgenetic alopecia
JP2010270083A (en) Antiseptic agent composition, use and preparation thereof, and formulation containing the same
CN109661224B (en) Compounds for reducing melanin content in cells
RU2018105153A (en) CANNING SYSTEM
WO2019115503A1 (en) Propanediol monoacetate mononitrate
EP3226827B2 (en) Aluminium-free antiperspirant/deodorant compositions and method of preparing the same
US10682301B2 (en) Use of 4-(3-ethoxy-4-hydroxyphenyl)alkylketone as a skin-soothing agent
RU2328324C2 (en) Method of cosmetic defect elimination and age-specific skin change prevention
JP2016525128A (en) How to protect your skin from environmental stressors
JP2010116376A (en) Cosmetic
JPH0977653A (en) Cosmetic
JP2006008550A (en) Antiaging agent
JP2016534041A (en) A method for adjusting the condition of the scalp to reduce dandruff

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20151216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WOODLAND, FREDERIC

Inventor name: VIC, GABIN

Inventor name: OSOLIN, FABRICE

Inventor name: LEGENDRE, JEAN-YVES

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170313

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20170901

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 968543

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180215

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014020766

Country of ref document: DE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2666903

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180508

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180207

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 968543

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180507

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180508

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180607

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180507

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014020766

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20181108

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180630

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180630

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180620

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140620

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180207

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20230510

Year of fee payment: 10

Ref country code: FR

Payment date: 20230510

Year of fee payment: 10

Ref country code: DE

Payment date: 20230425

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230427

Year of fee payment: 10

Ref country code: ES

Payment date: 20230707

Year of fee payment: 10